Clinical Trial Results:
            Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of  oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day combination therapy with Tipranavir or Lopinavir based HAART-regimen
    
|     Summary | |
|     EudraCT number | 2005-004698-39 | 
|     Trial protocol | DE | 
|     Global completion date | 
                                    12 Sep 2007
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    06 Apr 2018
                             | 
|     First version publication date | 
                                    06 Apr 2018
                             | 
|     Other versions | |
|     Summary report(s) | Statement | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
